Tenx

Stato
Chiusa ad ulteriori risposte.
Shares of Tenax Therapeutics Inc. were down 18% at $2.10 Tuesday after the company said it plans to offer stocks and warrants in a Monday filing with the Securities and Exchange Commission.

The specialty pharmaceutical company intends to use proceeds to progress the clinical development and regulatory approval of imatinib for the treatment of pulmonary arterial hypertension, and levosimendan for the treatment of heart failure with preserved ejection fraction, among other uses.
The company did not disclose the expected number of shares or warrants to be offered or the anticipated purchase price.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
 
il supporto ha tenuto benissimo

1674593389276.png
 
oggi no :rolleyes:

This is a best efforts public offering of up to: (i) 5,803,571 shares of our common stock, par value $0.0001 per share (the “Common Stock”) and (ii) Common Stock purchase warrants to purchase up to an aggregate of 11,607,142 shares of Common Stock (the “Warrants”) at an assumed combined public offering price of $2.24 per share of Common Stock and accompanying Warrant (which is based on the closing price of our Common Stock of $2.24 per share as reported by the Nasdaq Capital Market on January 27, 2023).

For purposes of clarity, each share of Common Stock or Pre-Funded Warrant to purchase one share of Common Stock is being sold together with a Warrant to purchase two shares of Common Stock. The Warrants will be immediately exercisable and will expire five years after their initial exercise date. The shares of Common Stock, and as applicable, Pre-Funded Warrants, can be purchased only with the accompanying Warrants, but will be issued separately, and will be immediately separable upon issuance.



Our Common Stock is listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “TENX.” The last reported closing price for our Common Stock on Nasdaq on January 27, 2023 was $2.24 per share. None of the Warrants or Pre-Funded Warrants are listed on a national securities exchange. We do not intend to apply to list Warrants or Pre-Funded Warrants on any national securities exchange. Without an active trading market, the liquidity of the Warrants or Pre-Funded Warrants may be limited.
 
adesso che ci siamo cavati il dente possiamo ripartire dal rapporto di zacks
https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_11032022_TENX_Vandermosten.pdf
1675285409585.png

questi sono numeri antecedenti l'rs. adesso i 79 milioni e rotti di titoli (warrant compresi) sono diventati poco meno di 4 milioni
l'offering prevede 5.8 milioni di nuovi titoli per un totale di poco meno di 10 milioni. il valore della società stimato da zacks era di 325 milioni di usd, che non hanno subito un rs, quindi resta uguale. 325/10 resta 32-33 usd per azione, con i soldi in cassa per la fase 3

se poi saranno approvati
1675285836985.png
 
Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
February 01, 2023 16:31 ET | Source: Tenax Therapeutics
  • Patent is expected to provide additional intellectual property protection until 2040
  • Prevalence estimates indicate that PH-HFpEF affects over 1,500,000 patients in the U.S.
  • There are currently no FDA approved treatments for PH-HFpEF
CHAPEL HILL, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application with claims covering the use of IV levosimendan in the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). The new claims were made in Tenax Therapeutics’ patent application titled “LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF).”


The patent is expected to last until 2040 and will provide the Company with substantial added intellectual property (IP) protection for the use of levosimendan in the treatment of PH-HFpEF patients in the United States. This Notice of Allowance further builds upon the Company’s significant IP for levosimendan, which includes U.S. Patent No. 11,213,524 that was issued in January 2022 and covers all medical uses in humans of the subcutaneous formulation of levosimendan.

Chris Giordano, Tenax Therapeutics’ Chief Executive Officer, stated, “This notice of allowance represents an important milestone in the Company’s development of broad IP protection for the use of levosimendan to treat the estimated 1.5 million-plus patients in the United States who suffer from PH-HFpEF and who currently have no FDA approved therapies to treat their condition. The protections this patent will provide are based on key discoveries from the HELP Study – the first study to demonstrate improved exercise tolerance in patients with this deadly disease. USPTO’s acknowledgement of the novelty of this targeted use of levosimendan increases our confidence that our pending patent applications, which are based on further data from the HELP patients who transitioned from IV to oral levosimendan, will also be afforded IP protection.”

The results of the HELP Study showed that levosimendan-treated PH-HFpEF patients benefited from a statistically significant improvement in 6-minute walk distance of 29 meters (p=0.03) when compared with placebo. When transitioning to the oral daily formulation after a lengthy treatment with the weekly IV formulation, the 6-minute walk results improved further. FDA has confirmed to Tenax Therapeutics that the six-minute walk distance endpoint is acceptable for a Phase 3 registration program for the treatment of PH-HFpEF.

Dr. Stuart Rich, Chief Medical Officer of Tenax Therapeutics, stated, “A recent American Heart Association Science Advisory* remarked that PH-HFpEF is a growing epidemic with high mortality that must be met with novel solutions. Levosimendan is the first therapy to show clinical benefit in a randomized controlled trial in this population. We expect the granting of this IP protection will allow us to proceed with the development of a desperately needed treatment for these patients.”

* Brittain, Evan L., et al. "Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Call to Action: A Science Advisory From the American Heart Association." Circulation 146.7 (2022): e73-e88
 
Sono assai tentato, visto il profondo rosso in cui versa a livello di percentuale di perdita nel mio ptf, di sfruttare lo squeeze per limitare i danni, accumulare minus e rientrare dopo, quando le prese di beneficio si faranno sentire
 
in premarket sta facendo un +3
$ non % :D:D:D
 
Pare abbia pizzicato 6 per un attimo. Anche se spesso il PRE è poco indicativo. Recentemente aveva fatto un +100% in pre diventato una perdita, seppur di poco, nell' orario ordinario.
 
Ho cancellato il mio precedente msg in quanto avevo letto soltanto i vs. ultimi tre :sleep:....scusate :bow:....
 
i volumi mi sembrano un po' eccessivi per il premarket, temo che si stiano divertendo a scambiarsi titoli e oggi farà un flop :rolleyes:

1675341255602.png
 
Per Cocorito troppo tardi per entrare con un chip?
è come se mi chiedessi di farti l'oroscopo :D
non ho la più pallida idea di quello che farà oggi.
sul lungo termine, credo abbastanza in quello che ho scritto nelle considerazioni su zacks
 
magari va pure a chiudere il gap :)
 
adesso che ci siamo cavati il dente possiamo ripartire dal rapporto di zacks
https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_11032022_TENX_Vandermosten.pdf
Vedi l'allegato 2876075
questi sono numeri antecedenti l'rs. adesso i 79 milioni e rotti di titoli (warrant compresi) sono diventati poco meno di 4 milioni
l'offering prevede 5.8 milioni di nuovi titoli per un totale di poco meno di 10 milioni. il valore della società stimato da zacks era di 325 milioni di usd, che non hanno subito un rs, quindi resta uguale. 325/10 resta 32-33 usd per azione, con i soldi in cassa per la fase 3

se poi saranno approvati
Vedi l'allegato 2876076
Grazie Cocorito! Quindi danno un tp di 32/33$ ad azione se acquisita e se invece viene approvato anche meglio?
 
Stato
Chiusa ad ulteriori risposte.
Indietro